Kshitij Rishi (4basecare): 10 Key Things You Must Know

Overview

Kshitij Rishi is a prominent figure in the biotechnology sector, particularly in the field of oncology. A co-founder of 4baseCare, he has been instrumental in advancing precision oncology solutions that focus on genetic profiling to personalize cancer treatments. This approach not only enhances treatment effectiveness but also aligns with global trends toward personalized medicine. Rishi's work has gained recognition within and outside the healthcare industry, making his company a notable player in the genomics segment. This article will explore the various facets of his work and contributions through 4baseCare.

Early Career and Foundation of 4baseCare

Educational Background and Initial Career
- Kshitij Rishi holds a post-graduate degree in Business Management from XLRI Jamshedpur, a prestigious institution in India. His academic background laid the foundation for his analytical thinking and strategic planning skills.
Venturing Into Genomics
- Before co-founding 4baseCare, Rishi garnered experience in various sectors, including healthcare and consultancy. His tenure at GE Healthcare enabled him to build a robust network and gain insights into the healthcare industry, particularly in genomics.
Founding of 4baseCare
- Together with Hitesh Goswami, Rishi founded 4baseCare in 2018. Their vision was to leverage genomics and next-generation digital health technologies to personalize oncology care. The company aims to address gaps in the oncology domain by integrating genetic data into treatment plans.

Precision Oncology and Genomic Profiling

Innovative Solutions in Oncosolutions
- 4baseCare specializes in developing genomic panels, such as the TARGT Indiegene, designed to cater specifically to the Indian population. This initiative addresses the lack of indigenous genomic data that often hinders personalized treatment plans.
Research & Development Initiatives
- The company has significantly invested in R&D to improve its genomic profiling capabilities. With backing from Illumina’s accelerator, 4baseCare is at the forefront of using Whole Exome and Transcriptome sequencing to tailor cancer treatment.

Strategic Partnerships and Expansions

Partnerships with Global Leaders
- 4baseCare has formed strategic alliances with various organizations, including Infosys and Innovate Life Sciences, to enhance its research capabilities and geographical reach. These collaborations facilitate technology transfer and the development of cutting-edge genomic testing solutions.
Global and Regional Expansion
- With operations expanding into Southeast Asia and the Middle East, 4baseCare aims to make precision oncology solutions accessible globally. The establishment of genomic labs in regions like Dubai exemplifies their commitment to broadening their impact.

Funding and Financial Milestones

Series A Funding and Investor Support
- Recently, 4baseCare secured $6 million in Series A funding led by Yali Capital. This funding aims to enhance product offerings and expand operations, thereby accelerating the delivery of personalized oncology solutions.
Investment from Infosys Innovation Fund
- Infosys invested INR 8.3 crore (~$1 million) with an aim to leverage 4baseCare's capabilities in precision oncology to augment its own healthcare solutions portfolio.

Conclusion

Kshitij Rishi's journey with 4baseCare highlights the increasing importance of precision medicine in modern healthcare. By focusing on genomics and collaborations, the company aims to fill critical gaps in oncology care. The future looks promising as 4baseCare continues to expand its reach and refine its services, offering hope and improved outcomes for cancer patients worldwide.